Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer

Cell-free DNA (cfDNA) extracted from peripheral blood has emerged as a crucial biomarker source in oncology research. To enhance the detection of somatic copy number alterations (SCNAs) and circulating tumor DNA (ctDNA), we developed eSENSES, a 2 Mb breast cancer-targeted NGS panel. It includes 15,000 genome-wide SNPs, 500 focal SNPs in breast cancer driver regions, and exons from 81 commonly altered genes, alongside a custom computational approach. We assessed the performance of eSENSES using both synthetic and clinical samples showing that eSENSES can detect ctDNA levels below 1%, exhibiting high sensitivity and specificity at 2-3% ctDNA levels. In patients with metastatic breast cancer, ctDNA estimations correlated with disease progression. When compared with other technologies and state-of-the-art approaches, eSENSES demonstrated enhanced performance. eSENSES provides a reliable, powerful and cost-effective tool for monitoring disease progression and guiding therapeutic decisions in breast cancer patients.

Authors

Institutions

Publication Details

Journal
npj Breast Cancer
Published
2025-03-08
DOI
https://doi.org/10.1038/s41523-025-00739-6
Citations
5
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
4.68

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer

Marta Pestrin, Matteo Benelli, Maria Inés Genovese, Marta Paoli et al.
5 citations
npj Breast Cancer
Cancer Genomics and Diagnostics
4.68
article

Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer

Marta Pestrin, Matteo Benelli, Maria Inés Genovese, Marta Paoli, Alessandro Romanel, Dario Romagnoli, Laura Biganzoli, Agostina Nardone, Francesca Galardi, Chiara Biagioni, Nicola Casiraghi, Riccardo Scandino, Erica Moretti, Luca Malorni, Ilenia Migliaccio, Andrea Tonina
article en
5 citations

Abstract

Cell-free DNA (cfDNA) extracted from peripheral blood has emerged as a crucial biomarker source in oncology research. To enhance the detection of somatic copy number alterations (SCNAs) and circulating tumor DNA (ctDNA), we developed eSENSES, a 2 Mb breast cancer-targeted NGS panel. It includes 15,000 genome-wide SNPs, 500 focal SNPs in breast cancer driver regions, and exons from 81 commonly altered genes, alongside a custom computational approach. We assessed the performance of eSENSES using both synthetic and clinical samples showing that eSENSES can detect ctDNA levels below 1%, exhibiting high sensitivity and specificity at 2-3% ctDNA levels. In patients with metastatic breast cancer, ctDNA estimations correlated with disease progression. When compared with other technologies and state-of-the-art approaches, eSENSES demonstrated enhanced performance. eSENSES provides a reliable, powerful and cost-effective tool for monitoring disease progression and guiding therapeutic decisions in breast cancer patients.

npj Breast CancerVol. 11(1)
University of Trento (IT), Hospital of Prato (IT), University of Florence (IT)
Ministero della Salute
Good health and well-being
Openalex Percentile: Top 5%
Cancer Genomics and Diagnostics
4.68
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.